Evolocumab

Comercialización: Repatha: Europa (EMA), EE.UU. (FDA)

Filtros

Seleccione alguna de las opciones para acotar la búsqueda

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension (FOURIER OLE)

Estado: Completado

Global Assessment of Plaque regression With a PCSK9 antibody as Measured by intravascular Ultrasound (GLAGOV)

Estado: Completado

EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

Estado: Otros

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Estado: Completo

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

Estado: Completo

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

Estado: Completo

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Estado: Completo

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3)

Estado: Completo

Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

Estado: Completo

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 (RUTHERFORD-2)

Estado: Completo

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-2 (GAUSS-2)

Estado: Completo

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)

Estado: Completo

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS)

Estado: Completo

LDL-C Assessment with PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

Estado: Completo

Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH). (HAUSER-OLE)

Estado: Completo

Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia

Estado: Completo

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia (BANTING)

Estado: Completo

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)) (ANITSCHKOW)

Estado: Completo

A Double-blind, Randomized Study in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia (BERSON)

Estado: Completo

Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI

Estado: Reclutando

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Estado: Reclutando

A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy

Estado: Otros

Lipid Management in Renal Transplant Recipients Using Evolocumab

Estado: Activo, no reclutando